Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922204 · ClinicalTrials.gov registry record · Phase 1
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
A Phase 1 study, sponsored by Merus B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT03922204: Completed Phase 1 study, sponsored by Merus B.V..
NCT03922204 is a Phase 1 study that has completed, run by Merus B.V.. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03922204, a Phase 1 study, has completed, sponsored by Merus B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients with advanced metastatic solid tumors or B-cell lymphomas. The study will be conducted in 2 parts.
Interventions
- DRUG Pembrolizumab (Keytruda)
- DRUG MCLA-145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2024-11-07 |
| Phase | Phase 1 |
What the finished NCT03922204 record still lists
NCT03922204 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab (Keytruda) is the first listed.
NCT03922204 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03922204 about?
NCT03922204 is a clinical study titled "A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies". This is an open-label, non-randomized, Phase 1 study to determine the safety, tolerability, and preliminary efficacy of MCLA-145 in adult patients with advanced metastatic solid tumors or B-cell lymphomas. The study will be conducted in 2 parts.
What is the current status of trial NCT03922204?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2019-05-08. Estimated completion is 2024-11-07.
What interventions are being tested in trial NCT03922204?
The interventions under investigation include: Pembrolizumab (Keytruda) (DRUG), MCLA-145 (DRUG).
Who is sponsoring clinical trial NCT03922204?
This trial is sponsored by Merus B.V., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03922204's enrollment target sits among peer trials
72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI